Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High‐Risk Recurrence Factors: A Phase II Single‐Center Prospective Study.
Saved in:
| Title: | Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High‐Risk Recurrence Factors: A Phase II Single‐Center Prospective Study. |
|---|---|
| Authors: | Tian, Yitong1,2 (AUTHOR), Lei, Tian1 (AUTHOR), Ruan, Qingyang3 (AUTHOR), Zhou, Xueying1,2 (AUTHOR), Shen, Ruijing1,2 (AUTHOR), Xie, Tianao1,2 (AUTHOR), Li, Shijie1,2 (AUTHOR), Cai, Xiujun1,2 (AUTHOR) srrsh_cxj@zju.edu.cn, Chen, Mingyu1,2 (AUTHOR) mychen@zju.edu.cn |
| Source: | Cancer Medicine. Apr2026, Vol. 15 Issue 4, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
